An observational study in Bacterial Infections and Gram-Negative Bacterial Infections, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This cross-sectional study aims to detect colistin heteroresistance phenotypically and genotypically among multidrug-resistant Gram-negative bacilli isolated from clinical specimens at Assiut University Hospitals.
Multidrug-resistant Gram-negative bacterial infections are a major clinical concern. Colistin is used as a last-line therapy, but heteroresistance (presence of resistant subpopulations within a susceptible isolate) may lead to treatment failure and is difficult to detect by routine methods.
This observational study will collect multidrug-resistant Gram-negative isolates that are intermediate to colistin by broth microdilution and will test them for heteroresistance using population analysis profile as the reference method, in addition to gradient strips (Etest) and disc diffusion. Molecular detection of related resistance genes will also be performed.
59 studies on the registry are indexed under Gram-Negative Bacterial Infections; 11 are open to participants now.
This study's planned enrollment of 75 is below the median of 249 across 14 observational studies indexed under Gram-Negative Bacterial Infections.
Browse Gram-Negative Bacterial Infections studies →Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Gram-Negative Bacterial Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bacterial Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Multidrug-resistant Gram-negative bacterial isolates obtained from clinical specimens of hospitalized patients at Assiut University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinical isolates of multidrug-resistant Gram-negative bacilli that are intermediate to colistin and will be tested for heteroresistance.
Number of isolates with colistin heteroresistance
Number of multidrug-resistant Gram-negative isolates showing colistin heteroresistance by population analysis profile test.
Time frame: Baseline
Number of isolates positive by Etest
Number of isolates showing colistin heteroresistance by gradient strip (Etest) method.
Time frame: Baseline
Number of isolates positive by disc diffusion
Number of isolates showing colistin heteroresistance by disc diffusion method.
Time frame: Baseline
Number of isolates carrying colistin heteroresistance-related genes
Number of isolates positive for genes associated with colistin heteroresistance detected by conventional polymerase chain reaction.
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gram-Negative Bacterial Infections →